Fig. 1 · Structure

Documents & Downloads

Eprosartan

Cat. No. A11121 CAS 133040-01-4

AT1 receptor antagonist

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Eprosartan Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Eprosartan from 3 published references. In vitro models include PC3 cells; human HepG2 cells.

Eprosartan In Vitro Studies

Eprosartan treatment of PC3 cells at 200 µM induced peak LC3-II expression at 96 h, with 11.1-fold increases. In PA-treated human HepG2 cells, Eprosartan at 5–20 μM did not show the restoration of insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3 observed with azilsartan and candesartan. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Eprosartan and LC3-II expression in PC3 cells

Cell-based study · PC3 cells [1]

PC3 cells were treated with Eprosartan at 200 µM. LC3-II expression peaked at 96 h, with 11.1-fold increases.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
expression of LC3-IILC3-II expression 200 µM; 96 h: 11.1-fold increases[1]

Literature-Reported Treatment Conditions

Treatment concentration
200 µM
Exposure duration
0, 24, 48, 72 and 96 h
Method
treated
Reported limits
Not stated in the sentences used: vehicle, control.
Methods and source locations

Compound reported in the paper: Eprosartan

Evidence for Eprosartan as the mesylate form reported in the paper, not the free base/neutral form supplied as A11121; no salt equivalence, dose conversion or lot validation.

Materials and methods > Untitled > Reagents (S2); Materials and methods > Untitled > Protein extraction and western blotting (S14); Results > Untitled > Autophagy-induced cell death in ARB-treated PC3 cells (S78, S79); Figure 2. legend (S100)

expression of LC3-II: expression of LC3-II — Results > Untitled > Autophagy-induced cell death in ARB-treated PC3 cells (S78, S79)

Eprosartan and insulin-stimulated phosphorylation in HepG2 cells

Cell-based study · human HepG2 cells [2]

HepG2 cells were treated for 16 h with 0.5 mM PA and three concentrations (5–20 μM) of nine FDA-approved ARBs. Azilsartan and candesartan fully restored the insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3 in PA-treated HepG2 cells, whereas eprosartan did not have those effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3Reported result 5–20 μM; 0.5 mM PA; 16 h: azilsartan and candesartan fully restored the insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3 in PA-treated HepG2 cells, whereas eprosartan did not have those effects.[2]

Literature-Reported Treatment Conditions

Treatment concentration
5–20 μM
Exposure duration
for 16 h, followed by treatment with 100 nM insulin for 15 min
Vehicle
DMSO
Co-treatment
Other interventions in this design: PA 0.5 mM; insulin 100 nM. Compound effect isolated by the comparison: treated with or without 0.5 mM PA and the indicated concentrations of ARBs.
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Eprosartan

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Angiotensin receptor blockers (ARBs) (S12); Results > Certain ARBs can alleviate insulin resistance in PA-treated HepG2 cells by attenuating lipid accumulation and intracellular Ca2+ overload (S46, S49)

insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3: insulin-stimulated phosphorylation of Akt, GSK3β, and FOXO3; comparator: 0.5 mM PA — Results > Certain ARBs can alleviate insulin resistance in PA-treated HepG2 cells by attenuating lipid accumulation and intracellular Ca2+ overload (S46, S49)

Eprosartan In Vivo Studies

Adult male Wistar albino rats undergoing torsion/detorsion received oral Eprosartan at 30 or 60 mg/kg. Testicular GSH increased to 2.63 mmol/g and 3.17 mmol/g, respectively, compared with the torsion/detorsion group. [3]

Eprosartan and testicular GSH in rats following torsion/detorsion

Animal study · Adult male Wistar albino rats; torsion/detorsion; n = 6 [3]

Adult male Wistar albino rats undergoing torsion/detorsion received oral Eprosartan at 30 or 60 mg/kg. Testicular GSH increased to 2.63 mmol/g and 3.17 mmol/g, respectively, compared with the torsion/detorsion group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
testicular GSHGSH level 2.63 mmol/g and 3.17 mmol/g[3]

Conditions shared by the study groups

Route
orally
Treatment course
one hour before T/D
Vehicle
1% aqueous solution of carboxymethylcellulose (CMC)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Eprosartan 30 or 60 mg/kgT/D groupAdministration of eprosartan (30 or 60 mg/kg) evinced a substantial elevation (p < 0.0001) in the level of GSH to 2.63 mmol/g and 3.17 mmol/g, respectively compared to T/D group.[3]
Eprosartan 30 or 60 mg/kg
Model: Adult male Wistar albino rats; torsion/detorsion; n = 6
Methods and source locations

Compound reported in the paper: Eprosartan

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Drugs and chemicals (S2); Materials and methods > Animals (S3); Materials and methods > Experimental testicular torsion/detorsion (T/D) procedures (S19); Results > Influence of eprosartan treatment on oxidative stress parameters (S116); Figure 1 legend (S154); Figure 5 legend (S171, S172)

testicular GSH: testicular GSH; comparator: T/D group — Results > Influence of eprosartan treatment on oxidative stress parameters (S116); Figure 5 legend (S171)

Eprosartan 30 or 60 mg/kg · Materials and methods > Experimental testicular torsion/detorsion (T/D) procedures (S19); Results > Influence of eprosartan treatment on oxidative stress parameters (S116)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 133040-01-4
Applications AT1 receptor antagonist
Formula C23H24N2O4S
Molecular Weight 424.5
Synonyms Teveten
SMILES
CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)/C=C(\CC3=CC=CS3)/C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Eprosartan Research References

  1. [1] Woo Y, Jung YJ. Angiotensin II receptor blockers induce autophagy in prostate cancer cells. Oncol Lett (2017). PMID: 28529582 DOI: 10.3892/ol.2017.5872 Source material
  2. [2] Lee JW, Gu HO, Jung Y, et al. Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation. Exp Mol Med (2023). PMID: 37121975 DOI: 10.1038/s12276-023-00982-6 Source material
  3. [3] Abu-Baih RH, Abu-Baih DH, Abdel-Hafez SMN, et al. Activation of SIRT1/Nrf2/HO-1 and Beclin-1/AMPK/mTOR autophagy pathways by eprosartan ameliorates testicular dysfunction induced by testicular torsion in rats. Sci Rep (2024). PMID: 38822026 DOI: 10.1038/s41598-024-62740-6 Source material

Added to your cart

View Cart Checkout
Loading...